The Food and Drug Administration today released draft guidance for assessing risk evaluation and mitigation strategies. FDA may require a REMS before approving certain drugs, including biologics, to help ensure its benefits outweigh its risks. FDA Commissioner Scott Gottlieb, M.D., said the guidance provides a framework for companies to develop an assessment plan when they develop a REMS program to improve the quality of the information used to assess the program’s effectiveness and provide post-market evidence that the REMS is meeting its risk mitigation goals. “We need to make sure that the REMS are achieving their public health goals, and that we’re designing and implementing these approaches in ways that minimize burdens to patients and providers,” he said.

Related News Articles

Headline
The Centers for Disease Control and Prevention today activated its Emergency Operations Center to support the interagency response to the Ebola outbreak in…
Headline
The World Health Organization has confirmed the first cases of Ebola in Uganda since 2013.
Blog
In this AHA Stat blog, Institute for Diversity and Health Equity President and CEO Duane Reynolds highlights various resources, programs and efforts to help…
Headline
President Trump yesterday signed legislation providing $19.1 billion in disaster relief for areas affected by hurricanes, wildfires and other recent natural…
Headline
The Centers for Disease Control and Prevention this week announced an anticipated shortage of Aplisol, one of two TB skin tests licensed by the Food and Drug…
Headline
The Centers for Disease Control and Prevention yesterday reported 1,001 cases of measles so far this year, according to the Department of Health and Human…